Engineering herpes simplex virus vectors for CNS applications.
about
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cellsCurrent approaches to enhance CNS delivery of drugs across the brain barriersA herpes simplex virus vector system for expression of complex cellular cDNA librariesGENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORSGene therapy for pain: results of a phase I clinical trial.Oncolytic herpes viruses as a potential mechanism for cancer therapy.Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons.Gene therapy for the treatment of sensory neuropathy.Herpes vector-mediated gene transfer in the treatment of chronic painApplications of gene therapy to the treatment of chronic pain.A human trial of HSV-mediated gene transfer for the treatment of chronic pain.Gene therapy for the treatment of diabetic neuropathy.HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain.A clinical trial of gene therapy for chronic pain.Targeted drug delivery to the peripheral nervous system using gene therapy.Neuroprotective effects of virally delivered HSPs in experimental stroke.Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors.Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion.Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain.
P2860
Q28766660-872FD6F9-163F-4042-BEE5-95140C7EDEA7Q30437835-01D46D67-35E9-4C4E-8545-BB6D7E18CE80Q33576519-DD549373-3599-4172-A555-724E8A7C938FQ33674877-0A5D8925-344B-475B-9354-06D3CCCE2D1EQ35154100-8985DD68-D2EA-4D0D-867F-F9B862079036Q35613495-26203DC4-5276-4A28-9A9A-A020B57FDC3BQ35875239-B0DD175B-913F-426B-86A5-43A02DA0C29DQ36446943-4B33DFA1-7886-4019-89B5-EE79885D1213Q37035292-59C44694-EBED-4E7F-B10B-ED629E096439Q37108334-6014BE17-DF19-4B19-90E7-680D077E54B9Q37195741-B32D42B1-C3DD-4E88-98CD-75A1CD3237E6Q37319721-98F0C45A-5C9A-4797-85C0-96AD11169193Q37439341-7FE9CA16-E9FA-4B53-AAA1-AF46ADD9858CQ37612033-46A5EC68-39D8-4D7B-9EBC-C0734BEDAEA5Q38008125-C2C9A769-E57B-4504-9407-DBBF4A70FB5BQ40389152-225C5B25-C385-4926-B071-613B4BEB32E7Q40755343-17C613CF-F079-4672-9F63-D0EDA2E62E0DQ43586557-15B2C935-8D47-4801-88DE-A54D7F15BC8BQ45803169-2B437CA6-EE12-4BF7-8096-D4E76CC6456C
P2860
Engineering herpes simplex virus vectors for CNS applications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Engineering herpes simplex virus vectors for CNS applications.
@ast
Engineering herpes simplex virus vectors for CNS applications.
@en
type
label
Engineering herpes simplex virus vectors for CNS applications.
@ast
Engineering herpes simplex virus vectors for CNS applications.
@en
prefLabel
Engineering herpes simplex virus vectors for CNS applications.
@ast
Engineering herpes simplex virus vectors for CNS applications.
@en
P2093
P356
P1476
Engineering herpes simplex virus vectors for CNS applications
@en
P2093
Glorioso JC
Moriuchi S
Oligino TJ
P356
10.1006/EXNR.1999.7158
P407
P577
1999-09-01T00:00:00Z